ATE285774T1 - Ranolazinhaltige arzneimittel mit verzögerter wirkstoffabgabe - Google Patents

Ranolazinhaltige arzneimittel mit verzögerter wirkstoffabgabe

Info

Publication number
ATE285774T1
ATE285774T1 AT99948196T AT99948196T ATE285774T1 AT E285774 T1 ATE285774 T1 AT E285774T1 AT 99948196 T AT99948196 T AT 99948196T AT 99948196 T AT99948196 T AT 99948196T AT E285774 T1 ATE285774 T1 AT E285774T1
Authority
AT
Austria
Prior art keywords
delayed release
products containing
medicinal products
ranolazine
containing ranolazine
Prior art date
Application number
AT99948196T
Other languages
German (de)
English (en)
Inventor
Andrew A Wolff
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26796494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE285774(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Application granted granted Critical
Publication of ATE285774T1 publication Critical patent/ATE285774T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
AT99948196T 1998-09-10 1999-09-09 Ranolazinhaltige arzneimittel mit verzögerter wirkstoffabgabe ATE285774T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9980498P 1998-09-10 1998-09-10
US09/321,522 US6303607B1 (en) 1998-09-10 1999-05-27 Method for administering a sustained release ranolanolazine formulation
PCT/US1999/020968 WO2000013687A2 (en) 1998-09-10 1999-09-09 Sustained release ranolazine formulations

Publications (1)

Publication Number Publication Date
ATE285774T1 true ATE285774T1 (de) 2005-01-15

Family

ID=26796494

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99948196T ATE285774T1 (de) 1998-09-10 1999-09-09 Ranolazinhaltige arzneimittel mit verzögerter wirkstoffabgabe
AT99968627T ATE217794T1 (de) 1998-09-10 1999-09-09 Ranolazinhaltige arzneimittel mit verzögerter wirkstoffabgabe

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT99968627T ATE217794T1 (de) 1998-09-10 1999-09-09 Ranolazinhaltige arzneimittel mit verzögerter wirkstoffabgabe

Country Status (33)

Country Link
US (14) US6303607B1 (OSRAM)
EP (3) EP1096937B9 (OSRAM)
JP (2) JP3745621B2 (OSRAM)
KR (1) KR100475759B1 (OSRAM)
CN (2) CN1211086C (OSRAM)
AR (3) AR022085A1 (OSRAM)
AT (2) ATE285774T1 (OSRAM)
AU (4) AU760435B2 (OSRAM)
BR (2) BR9913626A (OSRAM)
CA (2) CA2343376C (OSRAM)
CY (1) CY2008020I1 (OSRAM)
CZ (2) CZ301375B6 (OSRAM)
DE (3) DE69922964T2 (OSRAM)
DK (2) DK1096937T3 (OSRAM)
ES (2) ES2177346T3 (OSRAM)
FR (1) FR09C0001I2 (OSRAM)
GE (1) GEP20053420B (OSRAM)
HK (1) HK1044284B (OSRAM)
HU (2) HUP0104088A3 (OSRAM)
IL (6) IL141893A0 (OSRAM)
LU (1) LU91504I2 (OSRAM)
MX (2) MXPA01002599A (OSRAM)
NL (1) NL300371I2 (OSRAM)
NO (4) NO319434B1 (OSRAM)
NZ (2) NZ510386A (OSRAM)
PL (3) PL196263B1 (OSRAM)
PT (2) PT1109558E (OSRAM)
RU (2) RU2214233C2 (OSRAM)
SI (2) SI1109558T1 (OSRAM)
TR (2) TR200101261T2 (OSRAM)
TW (1) TWI241911B (OSRAM)
UA (2) UA67793C2 (OSRAM)
WO (2) WO2000013687A2 (OSRAM)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
MXPA02007639A (es) 2000-02-18 2004-08-23 Cv Therapeutics Inc Inhibidores de la oxidacion parcial de los acidos grasos en el tratamiento de la falla cardiaca congestiva.
US20020052377A1 (en) * 2000-07-21 2002-05-02 Wolff Andrew A. Method for treating angina
AU2001211213A1 (en) * 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
JP4732696B2 (ja) 2002-04-09 2011-07-27 フラメル・テクノロジー 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
AU2003246791A1 (en) * 2002-04-09 2003-10-20 Flamel Technologies Oral suspension of amoxicillin capsules
US20040063717A1 (en) 2002-05-21 2004-04-01 Andrew Wolff Method of treating diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
WO2006074398A2 (en) * 2005-01-06 2006-07-13 Cv Therapeutics, Inc. Sustained release pharmaceutical formulations comprising ranolazine
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
JP2009502957A (ja) * 2005-07-28 2009-01-29 スパーナス ファーマシューティカルズ インコーポレイテッド 機械的特性の向上した徐放性錠剤配合物
WO2007108362A1 (ja) * 2006-03-17 2007-09-27 Konica Minolta Holdings, Inc. 有機エレクトロルミネッセンス素子、表示装置および照明装置
FI20060501A7 (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi mahalaukussa
WO2008101012A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
JP2010518169A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 心血管疾患の処置のためのラノラジンの使用
US20080248112A1 (en) * 2007-02-13 2008-10-09 Brent Blackburn Use of ranolazine for the treatment of coronary microvascular diseases
ES2395241T3 (es) * 2007-03-07 2013-02-11 Concert Pharmaceuticals Inc. Derivados deuterados de piperazina como compuestos antianginosos
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
CN101896181A (zh) * 2007-05-31 2010-11-24 吉利德帕洛阿尔托股份有限公司 用于升高的脑钠肽的雷诺嗪
RU2442585C2 (ru) * 2007-05-31 2012-02-20 Си Ви Терапьютикс, Инк. Способ лечения диабета
CN101066253B (zh) * 2007-06-07 2011-01-05 北京本草天源药物研究院 一种雷诺嗪缓释片
AU2008266124A1 (en) * 2007-06-13 2008-12-24 Auspex Pharmaceuticals, Inc. Substituted piperazines
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20090076018A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ranolazine
WO2009100380A1 (en) * 2008-02-06 2009-08-13 Cv Therapeutics, Inc. Use of ranolazine for treating pain
WO2010132696A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
US8901128B2 (en) 2009-05-28 2014-12-02 Lupin Limited Pharmaceutical compositions of ranolazine
EP2480234B1 (en) 2009-09-25 2020-02-26 Lupin Limited Sustained release composition of ranolazine
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
ES2414384T3 (es) 2011-05-11 2013-07-19 Ratiopharm Gmbh Composición de liberación modificada que comprende ranolazina
NO3175985T3 (OSRAM) 2011-07-01 2018-04-28
AU2012312266A1 (en) 2011-09-21 2013-05-02 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
WO2014176567A2 (en) * 2013-04-26 2014-10-30 Chanrx Corporation Pharmaceutical compositions comprising vanoxerine and antianginal compounds, and methods of administration of the same for treating episodes of cardiac arrhythmia, maintaining normal sinus rhythm, preventing recurrence of cardiac arrhythmia, and treatment of chronic cardiac arrhythmia in mammals
CN104758265B (zh) * 2014-01-07 2019-05-17 四川海思科制药有限公司 一种雷诺嗪缓释片药物组合物及其制备方法
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
TW201717919A (zh) * 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
US10898444B2 (en) * 2017-06-01 2021-01-26 Sun Pharmaceutical Industries Limited Extended release multiparticulates of ranolazine
CN112438955A (zh) * 2019-08-30 2021-03-05 深圳翰宇药业股份有限公司 一种雷诺嗪缓释组合物及其制备方法
WO2021126884A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-pEF)
CN110898024A (zh) * 2019-12-17 2020-03-24 卓和药业集团有限公司 一种治疗心绞痛的药物组合物及制备方法
GR1010345B (el) * 2021-12-16 2022-11-28 Φαρματεν Α.Β.Ε.Ε., Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων
US20250064799A1 (en) 2021-12-31 2025-02-27 Tenax Therapeutics, Inc. Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
DK0719558T3 (da) * 1989-06-23 2002-10-07 Syntex Llc Ranolzin og beslægtede piperazin til anvendelse ved behandling af chocktilstande
US5527545A (en) 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JP2516524B2 (ja) * 1992-04-27 1996-07-24 大洋薬品工業株式会社 持続性製剤
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
JPH08259446A (ja) * 1995-01-24 1996-10-08 Mitsui Toatsu Chem Inc 持効性医薬製剤
JPH08310946A (ja) * 1995-05-19 1996-11-26 Yuutoku Yakuhin Kogyo Kk 経皮吸収製剤
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation

Also Published As

Publication number Publication date
US20050059667A1 (en) 2005-03-17
US20030099705A1 (en) 2003-05-29
ES2177346T3 (es) 2002-12-01
PL196668B1 (pl) 2008-01-31
US6617328B2 (en) 2003-09-09
US20020004506A1 (en) 2002-01-10
EP1109558A2 (en) 2001-06-27
IL141892A (en) 2006-08-20
FR09C0001I2 (OSRAM) 2009-12-18
MXPA01002599A (es) 2005-02-17
NL300371I2 (nl) 2009-10-01
HK1040060A1 (en) 2002-05-24
HUP0103844A3 (en) 2002-11-28
CA2342390C (en) 2006-08-29
WO2000013686A3 (en) 2000-07-06
US20030166659A1 (en) 2003-09-04
US20020090396A1 (en) 2002-07-11
EP1096937B1 (en) 2004-12-29
DE122008000065I1 (de) 2009-04-09
NO20011191D0 (no) 2001-03-08
HU224215B1 (hu) 2005-06-28
IL141893A0 (en) 2002-03-10
HUP0103844A2 (hu) 2002-04-29
JP3745621B2 (ja) 2006-02-15
PT1096937E (pt) 2005-04-29
HK1044284B (zh) 2005-07-15
LU91504I9 (OSRAM) 2019-01-02
KR100475759B1 (ko) 2005-03-10
US6864258B2 (en) 2005-03-08
IL141893A (en) 2008-08-07
FR09C0001I1 (OSRAM) 2009-02-27
AR052921A1 (es) 2007-04-11
NO20054324L (no) 2001-04-30
CZ2001880A3 (cs) 2001-08-15
AU6142599A (en) 2000-03-27
PL196263B1 (pl) 2007-12-31
AU744071B2 (en) 2002-02-14
CZ301341B6 (cs) 2010-01-20
TWI241911B (en) 2005-10-21
US20040029890A1 (en) 2004-02-12
NO20011192D0 (no) 2001-03-08
NO20011191L (no) 2001-04-30
DK1109558T3 (da) 2002-08-26
CZ301375B6 (cs) 2010-02-03
PL348249A1 (en) 2002-05-20
DE69901570D1 (de) 2002-06-27
BR9913626A (pt) 2001-12-04
NZ510384A (en) 2002-10-25
TR200101262T2 (tr) 2001-12-21
EP1109558B1 (en) 2002-05-22
EP1096937A2 (en) 2001-05-09
CA2343376C (en) 2007-01-09
AU2008207703A1 (en) 2008-09-25
KR20010089874A (ko) 2001-10-12
BR9913553A (pt) 2001-10-23
UA67793C2 (uk) 2004-07-15
PT1109558E (pt) 2002-10-31
CA2342390A1 (en) 2000-03-16
IL180864A0 (en) 2007-07-04
US6620814B2 (en) 2003-09-16
US20040097514A1 (en) 2004-05-20
DE69922964T2 (de) 2005-12-08
CN1211086C (zh) 2005-07-20
DE69922964D1 (de) 2005-02-03
CZ2001879A3 (cs) 2001-08-15
AU760435B2 (en) 2003-05-15
PL347073A1 (en) 2002-03-11
WO2000013686A2 (en) 2000-03-16
US6369062B1 (en) 2002-04-09
AR053440A2 (es) 2007-05-09
ATE217794T1 (de) 2002-06-15
LU91504I2 (fr) 2009-02-03
HUP0104088A3 (en) 2002-12-28
CN1321088A (zh) 2001-11-07
US6303607B1 (en) 2001-10-16
NO20011192L (no) 2001-04-30
NO2009005I1 (no) 2009-03-16
CY2008020I2 (el) 2010-07-28
HUP0104088A2 (hu) 2002-05-29
AU6036499A (en) 2000-03-27
MXPA01002598A (es) 2002-04-08
NO319434B1 (no) 2005-08-15
US20030100566A1 (en) 2003-05-29
EP1096937B9 (en) 2007-02-28
WO2000013687A3 (en) 2000-06-29
AU2008207707A1 (en) 2008-09-25
DK1096937T3 (da) 2005-05-09
UA75027C2 (uk) 2006-03-15
CN1354665A (zh) 2002-06-19
NL300371I1 (nl) 2009-02-02
WO2000013687A2 (en) 2000-03-16
CA2343376A1 (en) 2000-03-16
PL202207B1 (pl) 2009-06-30
GEP20053420B (en) 2005-01-25
US6562826B1 (en) 2003-05-13
HK1044284A1 (en) 2002-10-18
SI1096937T1 (en) 2005-04-30
JP2006096757A (ja) 2006-04-13
JP2002524416A (ja) 2002-08-06
AR022085A1 (es) 2002-09-04
TR200101261T2 (tr) 2002-05-21
US20060217397A1 (en) 2006-09-28
US20060147521A1 (en) 2006-07-06
NZ510386A (en) 2003-08-29
NO320986B1 (no) 2006-02-20
US6503911B2 (en) 2003-01-07
NO2009005I2 (OSRAM) 2010-06-28
IL175371A0 (en) 2006-09-05
ES2234302T3 (es) 2005-06-16
US6852724B2 (en) 2005-02-08
RU2214233C2 (ru) 2003-10-20
US6525057B2 (en) 2003-02-25
US20050153982A1 (en) 2005-07-14
CY2008020I1 (el) 2010-07-28
IL141892A0 (en) 2002-03-10
EP1527779A1 (en) 2005-05-04
SI1109558T1 (en) 2002-10-31
CN1193757C (zh) 2005-03-23
DE69901570T2 (de) 2003-01-09
RU2207856C2 (ru) 2003-07-10

Similar Documents

Publication Publication Date Title
ATE285774T1 (de) Ranolazinhaltige arzneimittel mit verzögerter wirkstoffabgabe
DE69908021D1 (de) Ziprasidonhaltige Arzneimittel
ATE202472T1 (de) Arzneimittel enthaltend oxaliplatin
DE69003568D1 (de) Arzneimittel mit verzoegerter freigabe.
DE69513671D1 (de) Arzneimittel
IL141456A0 (en) Rhodanine derivatives and pharmaceutical compositions containing the same
DE69737936D1 (de) Arzneimittel
ATE308319T1 (de) Dosierungsform mit verlängerter wirkstoffabgabe
DE59712694D1 (de) Stabilisiertes arzneimittel enthaltend cysteinylderivate
ATE237320T1 (de) Venlafaxinhaltiges arzneimittel mit verlängerter wirkstoffabgabe
AU2001269474A1 (en) Phenylpyridazine Compounds and Medicines Containing the Same
DE69937891D1 (de) Fluvastatin-arzneimittel mit verzögerter wirkstoffabgabe
ID27150A (id) Sediaan levotiroksin bahan farmasi
DE69430580D1 (de) Arzneimittel in nahrungsmittelform
DE69820861D1 (de) Teilchenförmige arzneimittelträger
DE69709349D1 (de) Arzneimittel bestehend aus diclofenac
GB9802088D0 (en) Pharmaceutical products
ATE219365T1 (de) Arzneimittel enthaltend mizolastin mit verzögerter wirkstoffabgabe
ATE384517T1 (de) Orales arzneimittel mit verzögerter wirkstoffabgabe
SG92726A1 (en) Thermosensitive trransfer film and method of using the same
AU2001294240A1 (en) 2,2-diphenylbutanamide derivatives and medicines containing the same
ATE269337T1 (de) Trizyclische delta3-pyridine als arzneimittel
DE59904727D1 (de) Verpackung mit Aufreissverschluss
AU2001274535A1 (en) Hydroxyformamidine derivatives and medicines containing the same
DE69906114D1 (de) Tablettenverpackungsartikel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1096937

Country of ref document: EP

EEIH Change in the person of patent owner